Hudson Bay Capital Management
AKRO

Hudson Bay Capital Management’s Akero Therapeutics AKRO Stock Holding History

Hudson Bay Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-85,000
Closed -$2.36M – 1282
2024
Q4 		$2.36M Buy
+85,000
New +$2.57M 0.01% 634

Other funds holding AKRO

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Hudson Bay Capital Management's AKRO Position: Q4 2025 in Review

Hudson Bay Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 338,500 shares — an estimated $16.1M sold.

Hudson Bay Capital Management first reported a position in AKRO in Q3 2024 and held it in 5 quarters. The position peaked at $20.6M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

  • Hudson Bay Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Hudson Bay Capital Management sold 338,500 Akero Therapeutics shares in Q4 2025, an estimated $16.1M.
  • Hudson Bay Capital Management first reported a position in Akero Therapeutics in Q3 2024 and held it in 5 quarters.
  • Hudson Bay Capital Management's Akero Therapeutics position peaked at $20.6M in Q2 2025.
  • 2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Hudson Bay Capital Management's 13F filing for Q4 2025, filed 13 Feb 2026.